Prospective randomized comparative trial of pefloxacin versus cotrimoxazole in the treatment of typhoid fever in adults

Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):361-3. doi: 10.1007/BF01962337.

Abstract

Pefloxacin, which has been shown to have a high in vitro activity against Salmonella spp., was compared to cotrimoxazole in the treatment of typhoid fever in adults. In a prospective, randomized trial, 42 patients with bacteriologically documented typhoid fever received either 400 mg pefloxacin b.i.d. or 160/800 mg cotrimoxazole b.i.d. Duration of treatment was 14 days in both groups. All patients were cured without experiencing a relapse or becoming a salmonella carrier. Apyrexia and resolution of digestive and neurological symptoms were obtained in a significantly shorter time with pefloxacin than with cotrimoxazole. Pefloxacin was well tolerated and more effective than cotrimoxazole in the treatment of typhoid fever.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Drug Combinations / pharmacology
  • Drug Combinations / therapeutic use
  • Female
  • Humans
  • Male
  • Norfloxacin / analogs & derivatives*
  • Norfloxacin / pharmacology
  • Norfloxacin / therapeutic use
  • Paratyphoid Fever / drug therapy*
  • Pefloxacin
  • Prospective Studies
  • Random Allocation
  • Salmonella paratyphi A / drug effects
  • Salmonella paratyphi A / isolation & purification
  • Salmonella paratyphi B / drug effects
  • Salmonella paratyphi B / isolation & purification
  • Salmonella typhi / drug effects
  • Salmonella typhi / isolation & purification
  • Sulfamethoxazole / pharmacology
  • Sulfamethoxazole / therapeutic use*
  • Trimethoprim / pharmacology
  • Trimethoprim / therapeutic use*
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Typhoid Fever / drug therapy*

Substances

  • Drug Combinations
  • Pefloxacin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Trimethoprim
  • Sulfamethoxazole
  • Norfloxacin